KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to $2.0 million.

  • Novavax's Capital Expenditures rose 4701.17% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year decrease of 7287.12%. This contributed to the annual value of $13.1 million for FY2024, which is 7571.74% down from last year.
  • Per Novavax's latest filing, its Capital Expenditures stood at $2.0 million for Q3 2025, which was up 4701.17% from $247000.0 recorded in Q2 2025.
  • In the past 5 years, Novavax's Capital Expenditures ranged from a high of $24.6 million in Q3 2022 and a low of $247000.0 during Q2 2025
  • For the 5-year period, Novavax's Capital Expenditures averaged around $11.3 million, with its median value being $12.2 million (2021).
  • In the last 5 years, Novavax's Capital Expenditures soared by 1092480.0% in 2021 and then crashed by 9244.41% in 2024.
  • Quarter analysis of 5 years shows Novavax's Capital Expenditures stood at $13.4 million in 2021, then soared by 72.08% to $23.0 million in 2022, then plummeted by 61.61% to $8.8 million in 2023, then crashed by 78.14% to $1.9 million in 2024, then rose by 4.4% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $247000.0 for Q2 2025, and $1.2 million during Q1 2025.